Canaccord Genuity
Canaccord Genuity is the global capital markets division of Canaccord Financial Inc. (CF : TSX | CF. : AIM), offering institutional and corporate clients idea-driven investment banking, research, sales and trading services.
The companies has operations in 24 cities worldwide and the ability to list companies on 10 stock exchanges.
View Older Stories View More Recent Stories
-
iAnthus Provides Update on Timing of Annual Filings and Required Interest Payments
-
Piedmont Lithium Limited Announces Closing of Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
-
Ducommun Incorporated (DCO) PT Raised to $46 at Canaccord Genuity
-
Granite Creek Copper Closes $710,000 Private Placement Financing
-
Canaccord Genuity Expands International Investment Banking Capability to Latin America and Caribbean
-
Bill.com (BILL) Prices 7.2M Share Upsized Follow-On Offering at $74.25/Sh
-
ChemoCentryx (CCXI) Prices 5.2M Share Common Offering at $58/Sh
-
Bill.com Announces Pricing of Upsized Follow-on Offering
-
ChemoCentryx Prices Public Offering of Common Stock
-
ChemoCentryx Prices Public Offering of Common Stock
-
Transaction in Own Shares
-
G2 Goldfields Inc. Announces Private Placement Financing
-
Net Asset Value(s)
-
TransGlobe Energy Corporation Announces Its Participation in the Virtual Summer Summit
-
Bill.com (BILL) Announces Launch of 3.25M Share Proposed Follow-on Offering of Common Stock
-
Bill.com Announces Launch of Proposed Follow-on Offering
-
Sundial Announces Successful Amendments with Senior Lenders, US$18 Million Convertible Notes Issuance and Close of Bridge Farm Sale
-
'Stay at home stock' Slack Technologies dips ahead of report
-
3iQ’s Bitcoin Fund Files New Issue Prospectus
-
ZoomInfo Technologies (ZI) IPO Opens 90% Higher
-
InterRent REIT Closes $230 Million Bought Deal Financing
-
Oncolytics Biotech (ONCY) Provides Recap of KOL Call Highlighting Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
-
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
-
UPDATE: ZoomInfo Technologies Inc. (ZI) Prices 44.5M Class A Share IPO at $21/Sh
-
ZoomInfo Announces Pricing of its Initial Public Offering
-
DraftKings Inc. (DKNG) PT Raised to 'Street High' $50 at Canaccord Genuity (Earlier)
-
TransGlobe Energy Corporation Announces Director/PDMR Shareholdings
-
Canaccord Genuity Group Inc. Reports Fourth Quarter Fiscal 2020 Results
-
Net Asset Value(s)
-
Shamrock Capital Announces Acquisition of Adweek
-
Kaleido Biosciences Inc. (KLDO) Prices 4.75M Share Common Offering at $7.50/Sh
-
Allogene Therapeutics (ALLO) Prices 11.7M Share Common Offering at $47/Sh
-
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
-
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
-
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
-
Form X-17A-5 CANACCORD GENUITY WEALTH For: Mar 31
-
Kaleido Biosciences Inc. (KLDO) to Offer Common Stock
-
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
-
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
-
Form X-17A-5 CANACCORD GENUITY LLC For: Mar 31
-
Total voting rights
-
Schultze Special Purpose Acquisition Corp. (SAMA) Announces Non-Binding Letter of Intent for Business Combination with Clever Leaves
-
Schultze Special Purpose Acquisition Corp. Announces Non-Binding Letter of Intent for a Business Combination with Clever Leaves, a Leading Pharmaceutical-Grade Multi-National Cannabis Operator
-
Atalaya Mining PLC Announces Junta de Andalucía Validates Mining Permits
-
Canaccord Genuity Assumes Bandwidth Inc. (BAND) at Buy
-
Canaccord Genuity Assumes Twilio (TWLO) at Buy
-
Canaccord Genuity Assumes Everbridge (EVBG) at Buy
-
Aleafia Health Announces Closing of $14.95 Million Bought Deal Offering, Including Full Exercise of the Over-Allotment Option
-
Repay Holdings Corporation (RPAY) Prices 8M Share Common Offering at $20/Sh

